S1P as regulator of neonatal mucosal immune development and injury
S1P作为新生儿粘膜免疫发育和损伤的调节剂
基本信息
- 批准号:10039799
- 负责人:
- 金额:$ 13.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-17 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AblationAddressAdultAdvisory CommitteesAffectAgeAgonistAnimal ExperimentsAnimal ModelAnimalsAppointmentAtypical lymphocyteBiochemistryBioinformaticsBiologyCell ProliferationCellsCeramidesChronicComplementDataDendritic CellsDevelopmentDevelopment PlansDiagnosisEmigrantEnvironmentEnzymesEventExposure toFacultyFecesFluorescent in Situ HybridizationFunctional disorderGerm-FreeGrantGut MucosaHumanHuman bodyITGAX geneImmuneImmunologyIndividualInfantInflammatoryInjuryInstitutionIntegration Host FactorsIntestinal DiseasesIntestinesKnockout MiceKnowledgeLamina PropriaLeadLesionLifeLymphocyteLymphocyte FunctionLymphopeniaManuscriptsMass Spectrum AnalysisMature T-LymphocyteMediatingMentored Research Scientist Development AwardMentorsMetabolismMicrobiologyModelingMolecular BiologyMorbidity - disease rateMucosal ImmunityMucous MembraneMusNecrotizing EnterocolitisNeonatalNewborn InfantOutcomePathologyPeripheralPharmacologyPhenotypePopulationPremature InfantPreparationPrevention strategyProcessProductionPublishingResearchResearch PersonnelRoleShapesSignal TransductionSignaling MoleculeSiteSmall IntestinesSpecimenSphingolipidsSphingosine-1-Phosphate ReceptorStimulusT-LymphocyteTestingThymus GlandTimeTissuesTrainingVery Low Birth Weight InfantWorkWritingbacterial communitybasecareercareer developmentcell typecohortcytokinedysbiosisfeedinggut bacteriagut microbiotahost-microbe interactionshuman datahuman microbiotahypoxia neonatorumimprovedin vivoinflammatory disease of the intestineinterestlymph nodesmature animalmetabolomicsmicrobialmicrobial communitymicrobiotamigrationmortalitymouse modelmucosal microbiotaneonatenovelpreventpupreceptorresidenceresponsesecondary lymphoid organskillssphingosine 1-phosphatethymocytetrafficking
项目摘要
SUMMARY
Dr. Rusconi has a long-standing interest in host microbial interactions. Her work has focused on infants born
preterm, who are exceptionally prone to life-threatening gut-associated pathology, most notably necrotizing
enterocolitis (NEC). The absence of preventive strategies for NEC and its abysmal outcomes, compelled Dr.
Rusconi to perform a broad range metabolomics analysis of pre-event NEC specimens to better understand its
pathophysiology. A unique sphingolipid profile emerged, which was confirmed in a larger cohort by targeted
mass spectrometry. Sphingolipids perform diverse functions in the human body. Sphingosine-1-phosphate
(S1P), a sphingolipid metabolite, is an important signaling molecule that promotes lymphocyte migration. The
sensing of S1P by S1P receptor 1 (S1P1) is antagonized in vivo by multiple S1P1 agonists, such as SEW2871,
through the internalization and degradation of the receptor. By treating neonatal mice with SEW2871 she
observed the predicted systemic lymphopenia and and increase in dendritic and T cells in the small intestine
lamina propria. The accumulation of these cells in the lamina propria was not observed in adult mice. Aim 1 will
focus on identifying age-specific functional responses of the small intestinal lamina propria upon S1P
antagonism. Dr. Rusconi will complement pharmacological data with cell-type specific S1P1 KO mice to address
cell-specific requirements. The sphingolipid signature and dysbiosis appear in the same pre-NEC interval. Aim
2 focuses on determining their relationship. Germ-free mice will be colonized with dysbiotic or control preterm
microbiota to assess impact on sphingolipids. Fecal content from animals used in Aim 1 will be used to determine
the impact of S1P antagonism on the microbiota. Finally, in Aim 3, Dr. Rusconi will combine S1P1 antagonism
and dysbiotic preterm microbiota with the NEC-like injury model. She will dissect the role of accumulating
lymphocyte populations and altered microbiota on exacerbating NEC-like lesions. Completion of this proposal
will provide much needed information on the role of S1P signaling in mucosal immunity establishment and its
interplay with the microbiota in the maturing intestine, an interval of life during which NEC occurs. Specifically,
this K01 award will allow Dr. Rusconi to improve her ability to plan and conduct animal experiments, refine her
immunology skills, and provide her with didactic and practical training in grant writing and manuscript preparation,
in a highly mentored environment. Dr. Rusconi’s Institution is supporting her effort with a junior faculty
appointment, space, and protected time to perform this work. Her advisory committee consists of her primary
mentor Dr. Phillip Tarr, co-mentors Drs. Rodney Newberry and Gautam Dantas, who are investigators with
complementary expertise in mucosal immunity, microbe-host interactions, animal models of intestinal disease,
and human microbiota modeling. Dr. Rusconi’s Career Development Plan adds to her training in biochemistry,
molecular biology, microbiology, and bioinformatics. In summary, this K01 grant will provide Dr. Rusconi the
skills to launch an independent research career, amalgamating bioinformatics and experimental biology.
概括
鲁斯科尼博士长期以来对宿主微生物相互作用感兴趣,她的工作重点是出生的婴儿。
早产儿,特别容易出现危及生命的肠道相关病变,尤其是坏死性病变
小肠结肠炎 (NEC) 缺乏针对 NEC 的预防策略及其糟糕的结果,迫使 Dr.
Rusconi 对事件前 NEC 样本进行广泛的代谢组学分析,以更好地了解其
出现了独特的鞘脂谱,并通过靶向研究在更大的队列中得到了证实。
鞘脂在人体内发挥多种功能。
(S1P) 是一种鞘脂代谢产物,是促进淋巴细胞迁移的重要信号分子。
S1P 受体 1 (S1P1) 对 S1P 的感知在体内被多种 S1P1 激动剂(例如 SEW2871)拮抗,
通过用 SEW2871 治疗新生小鼠,她通过受体的内化和降解。
观察到预测的全身淋巴细胞减少以及小肠中树突状细胞和 T 细胞的增加
在成年小鼠中未观察到这些细胞在固有层中的积累。
关注小肠固有层对 S1P 的年龄识别特异性功能反应
Rusconi 博士将用细胞类型特异性 S1P1 KO 小鼠补充药理学数据来解决这一问题。
神经鞘脂特征和菌群失调出现在相同的前 NEC 间隔中。
2 重点是确定无菌小鼠将被定植为菌群失调或对照早产小鼠。
将使用微生物群来评估目标 1 中使用的动物粪便含量的影响。
最后,在目标 3 中,Rusconi 博士将结合 S1P1 拮抗作用。
她将剖析积累的作用。
淋巴细胞群和微生物群的改变加剧了 NEC 样病变。 完成该提案。
将提供关于 S1P 信号在粘膜免疫建立中的作用及其作用的急需信息
与成熟肠道中的微生物群相互作用,这是 NEC 发生的生命周期。
这个K01奖将使Rusconi博士能够提高她计划和进行动物实验的能力,完善她的
免疫学技能,并为她提供资助写作和手稿准备方面的教学和实践培训,
在一个高度指导的环境中,鲁斯科尼博士的机构正在通过初级教师支持她的努力。
她的咨询委员会由她的主要成员组成。
导师 Phillip Tarr 博士,共同导师 Rodney Newberry 博士和 Gautam Dantas 博士,他们是研究人员
粘膜免疫、微生物与宿主相互作用、肠道疾病动物模型等方面的互补专业知识,
Rusconi 博士的职业发展计划增加了她在生物化学方面的培训,
分子生物学、微生物学和生物信息学 总之,这笔 K01 资助将为 Rusconi 博士提供
开展独立研究职业、融合生物信息学和实验生物学的技能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brigida Agnese Rusconi其他文献
Brigida Agnese Rusconi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brigida Agnese Rusconi', 18)}}的其他基金
S1P as regulator of neonatal mucosal immune development and injury
S1P作为新生儿粘膜免疫发育和损伤的调节剂
- 批准号:
10614963 - 财政年份:2020
- 资助金额:
$ 13.69万 - 项目类别:
S1P as regulator of neonatal mucosal immune development and injury
S1P作为新生儿粘膜免疫发育和损伤的调节剂
- 批准号:
10219246 - 财政年份:2020
- 资助金额:
$ 13.69万 - 项目类别:
S1P as regulator of neonatal mucosal immune development and injury
S1P作为新生儿粘膜免疫发育和损伤的调节剂
- 批准号:
10397640 - 财政年份:2020
- 资助金额:
$ 13.69万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
The role of dendritic cells in heart valve extracellular matrix remodeling, homeostasis, and disease
树突状细胞在心脏瓣膜细胞外基质重塑、稳态和疾病中的作用
- 批准号:
10672638 - 财政年份:2023
- 资助金额:
$ 13.69万 - 项目类别:
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
一种用于治疗 B 系急性淋巴细胞白血病/淋巴瘤的新型 VpreB1 抗体药物偶联物
- 批准号:
10651082 - 财政年份:2023
- 资助金额:
$ 13.69万 - 项目类别:
Genetic and molecular mechanisms of Xbp-1 mediated salivary gland development and differentiation
Xbp-1介导唾液腺发育和分化的遗传和分子机制
- 批准号:
10678146 - 财政年份:2023
- 资助金额:
$ 13.69万 - 项目类别:
Neural pathways for obesity development by AgRP neurons
AgRP 神经元导致肥胖发展的神经通路
- 批准号:
10681993 - 财政年份:2023
- 资助金额:
$ 13.69万 - 项目类别:
Mitochondrial proton leak and neonatal brain injury
线粒体质子泄漏与新生儿脑损伤
- 批准号:
10724518 - 财政年份:2023
- 资助金额:
$ 13.69万 - 项目类别: